Hookipa Pharma, a Phase 2 biotech developing T cell immunotherapies for various cancers, filed with the SEC to raise up to $86 million in an initial public offering.
The New York-based biopharma is developing immunotherapies for infectious diseases and cancer based on its proprietary arenavirus platform, designed to reprogram the body's immune system
The drugmaker's lead infectious disease product candidate, HB-101, is currently in a Phase 2 randomized, double-blinded clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Hoopika has entered into a strategic partnership with Gilead Sciences to accelerate building a pipeline of additional infectious disease product candidates in a cost-efficient manner.
Hoopika is supported by Baker Brothers, Sofinnova Partners and Forbion Capital Partners as major shareholders, as well as Boehringer Ingelheim Venture Fund, Takeda Ventures, HBM Partners and Redmile Group.
Read the press release